MAP kinases in chondrocyte differentiation  by Stanton, Lee-Anne et al.
Review
MAP kinases in chondrocyte differentiation
Lee-Anne Stanton,a,b T. Michael Underhill,a,b and Frank Beiera,b,*
a CIHR Group in Skeletal Development and Remodeling, Department of Physiology and Pharmacology,
University of Western Ontario, London, ON, Canada
b School of Dentistry, University of Western Ontario, London, ON, Canada
Received for publication 22 March 2003, revised 16 May 2003, accepted 20 May 2003
Abstract
The majority of the vertebrate skeleton develops through the process of endochondral ossification and involves successive steps of
chondrogenesis, chondrocyte proliferation, and hypertrophic chondrocyte differentiation. Interruption of this program through gene
mutations and hormonal or environmental factors contributes to numerous diseases, including growth disorders and chondrodysplasias.
While a large number of growth factors and hormones have been implicated in the regulation of chondrocyte biology, relatively little is
known about the intracellular signaling pathways involved. Recent data provide novel insights into the mechanisms governing acquisition
of new phenotypes within the chondrogenic program and suggest multiple pivotal roles for members of the mitogen-activated protein kinase
family and their downstream targets in cartilage development. These data are summarized and discussed here.
© 2003 Elsevier Inc. All rights reserved.
Chondrogenesis and endochondral ossification
The vertebrate skeleton is the end result of the well-
orchestrated and intricately controlled multistep differenti-
ation of mesenchymal cells (Cancedda et al., 1995, 2000;
Olsen et al., 2000). Three cell populations contribute to the
vertebrate skeleton. Neural crest cells give rise to craniofa-
cial bones, while the axial skeleton forms from the scle-
rotome compartment of the somites. The lateral plate me-
soderm yields the skeleton of the limbs. Each of these
skeletal elements is prefigured in mesenchymal condensa-
tions between 10.5 and 12.5 days postcoitum (dpc) in mice,
whereafter they can follow two pathways. The first being
differentiation of condensed cells directly into osteoblasts in
a process termed intramembraneous ossification. These
events result in the majority of the craniofacial bones and
the clavicles. In the remaining part of the future skeleton,
condensation of mesenchymal progenitor cells is followed
by differentiation of these cells into chondrocytes, in a
process termed chondrogenesis (Fig. 1). In a second step,
cartilage is replaced by bone tissue and bone marrow to give
rise to mature bones. The involvement of a cartilage inter-
mediate in this second process leads to the term endochon-
dral ossification.
Chondrogenesis is initiated by the condensation of mes-
enchymal precursor cells and is accompanied by expression
of molecules involved in cell–cell adhesion such as N-
cadherin (DeLise et al., 2000) (Fig. 2). This is followed by
the expression of chondrocyte-specific genes such as the
transcription factor Sox9 and genes encoding cartilage ex-
tracellular matrix proteins (e.g., collagen II, aggrecan).
Cells within the centers of these cartilage elements differ-
entiate further to become hypertrophic chondrocytes, which
are characterized by their large cell volume and expression
of specific marker genes such as collagen X (Kielty et al.,
1985; Reichenberger et al., 1991). The formation of a
growth plate adjacent to the zone of hypertrophy follows. In
the growth plate, chondrocytes proliferate mostly in a uni-
directional manner along the longitudinal axis of the later
bone, resulting in longitudinal bone growth. Under the con-
trol of several growth factors, chondrocytes eventually exit
the cell cycle and start to differentiate to hypertrophic chon-
drocytes. Late hypertrophic chondrocytes initiate the ex-
pression of many genes shared with osteoblasts (such as
matrix metalloproteinase 13 and bone sialoprotein; (Chen et
al., 1991; Gack et al., 1995) and mineralize their extracel-
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lular matrix. The fate of the hypertrophic chondrocytes is
debated since both apoptosis and further differentiation of
the cells into osteoblast-like cells has been described (Ad-
ams and Shapiro, 2002). However, it is generally accepted
that hypertrophic cartilage is degraded and replaced by bone
tissue, completing the process of endochondral ossification.
Endochondral ossification therefore consists of distinguish-
able phases of cell condensation, chondrogenesis, chondro-
cyte proliferation, hypertrophic chondrocyte differentiation,
and replacement of cartilage by bone tissue.
A large number of growth factors and hormones are
known to regulate chondrogenesis, chondrocyte prolifera-
tion, and hypertrophic differentiation (Fig. 1). These include
insulin-like growth factors (IGFs), transforming growth fac-
tor-beta (TGF-), bone morphogenetic proteins (BMPs),
parathyroid hormone-related peptide (PTHrP), indian
hedgehog, fibroblast growth factors (FGFs), and retinoic
acid (Cancedda et al., 1995; DeLise et al., 2000; Wagner
and Karsenty, 2001). Disruption of the signaling from many
of these factors results in various disease conditions, such as
chondrodysplasias, inherited diseases characterized by skel-
etal deformities and dwarfism (Mundlos and Olsen, 1997a
1997b). For example, activating mutations in the FGF re-
ceptor3 gene lead to decreased bone growth in human
achondroplasia and hypochondroplasia patients (Bellus et
al., 1995; Shiang et al., 1994). Growth plate activity also
controls linear growth and final length/height in vertebrates
(Frost and Schonau, 2001; Hunziker, 1994; Price et al.,
1994). Numerous growth abnormalities (e.g., as a result of
endocrine disorders or drug treatments) are associated with
disruption of normal growth plate function (Nilsson et al.,
1994; Ohlsson et al., 1993; Siebler et al., 2001, 2002; van
Leeuwen et al., 2000).
As in many other developmental programs, the timely
intracellular relay of extracellular signals is essential for
proper bone development. As outlined above, the number of
extracellular signals implicated in this process is continu-
ously expanding. In addition, Sox9 and Cbfa1 have been
identified as important transcriptional regulators of early
and late chondrogenic differentiation, respectively (de
Crombrugghe et al., 2001; Karsenty, 2001). In contrast,
relatively little is known about the intracellular signaling
pathways controlling chondrogenesis and chondrocyte dif-
ferentiation. Mitogen-activated protein kinases (MAPKs)
are among the most widespread and most studied signaling
pathways in eukaryotic cells. The recent increase in infor-
mation regarding their involvement in chondrocyte prolif-
eration and differentiation is the focus of this review.
MAP kinase cascades
The mitogen-activated protein kinases (MAPKs) are re-
sponsible for the conversion of a large number of extracel-
lular stimuli into specific cellular responses that range from
positive and negative roles in cell proliferation, differenti-
Fig. 1. Endochondral ossification. Endochondral ossification is initiated by the condensation of mesenchymal precursor cells and differentiation of these cells
into chondroblasts, giving rise to cartilage anlage of the latter bones. Cells in the centre of the anlagen differentiate further to hypertrophic chondrocytes, and
growth plates are formed at both sides of the hypertrophic zone. Mineralisation and vascular invasion of hypertrophic cartilage and apoptosis of hypertrophic
chondrocytes follow. Hypertrophic cartilage is then replaced by bone tissue. Growth plates continue to direct longitudinal growth of endochondral bones
through proliferation and hypertrophy of chondrocytes.
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ation, and apoptosis to regulation of inflammatory and stress
responses. The general biochemistry and biology of MAP
kinases are the subject of several recent reviews and are
therefore only briefly summarized here (Chen et al., 2001;
Cobb, 1999; Johnson and Lapadat, 2002; Kyriakis and
Avruch, 2001; Pearson et al., 2001; Robinson and Cobb,
1997; Schramek, 2002; Treisman, 1996). MAPK pathways
also coordinate regulation of gene transcription and protein
synthesis as well as adaptation to changes of the extracel-
lular environment. Multiple MAPK pathways exist in eu-
karyotic cells (Fig. 3). These pathways are activated by
distinct stimuli, including hormones and growth factors that
exert their effects through a diverse array of receptor fam-
ilies such as receptor tyrosine kinases, cytokine receptors, G
protein-coupled seven-transmembrane receptors, and
serine-threonine kinase receptors. It can therefore be appre-
ciated that the MAPK pathways exert a profound effect on
cell physiology (for review, see Kyriakis and Avruch, 2001;
Pearson et al., 2001).
All of the MAPK pathways are organised into cascades
that work in series to result in activation of the MAPK
following the concurrent phosphorylation of tyrosine (Tyr)
and threonine (Thr) residues within the conserved Thr-X-
Tyr motif in the activation loop of the kinase domain. The
cascade originates with the phosphorylation of several pro-
tein kinase families that are collectively referred to as the
MAPK-kinase-kinases (MAP3Ks) or MEK kinases
(MEKKs) (Hagemann and Blank, 2001; Kyriakis and
Avruch, 2001). These proteins in turn lead to activation of
a family of dual specificity kinases referred to as MAPK/
extracellular signal-regulated kinase kinases (MEKS or
MKKs; MAP2Ks), and it is this family that catalyses the
phosphorylation and activation of the MAPKs. Activation
of MAP kinases is often accompanied by translocation to
the nucleus. MAP kinase substrates include cytoplasmic
proteins such as heat shock proteins as well as various
transcription factors and downstream kinases.
Three major MAPK families have been identified to date
in mammalian cells. They have been categorised according
to the amino acid (X) in the dual phosphorylation site
(TXY). These families are (1) ERK1 and ERK2, often
referred to as p44 and p42 respectively (X  Glu); (2) JNK
(JNK1/2/3) or SAPK (X Pro); and (3) p38 MAPK (p38/
//) (X  Gly). Additional MAP kinases such as ERK5
have been described, but less is known about their function
Fig. 3. Organization of mammalian MAP kinase pathways. Following
stimulation of receptors, phosphorylation of MAP3K leads to MAP2K
phosphorylation and activation that subsequently results in MAPK phos-
phorylation and activation. Phosphorylation of appropriate substrates and
transcription factors causes specific biological responses such as changes in
cell proliferation and differentiation or gene expression.
Fig. 2. Schematic representation of the chondrogenic program. Chondro-
genesis starts with the condensation of mesenchymal precursor cells, fol-
lowed by chondrogenic differentiation within the condensations. A subset
of chondroblasts then initiates proliferation and subsequently undergoes
hypertrophic differentiation. Each stage is characterized by expression of
specific marker genes shown on the right. In particular, the expression
pattern of two important transcriptional regulators of chondrocyte differ-
entiation, Sox9 and Cbfa1, is indicated.
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and regulation. The MAPK nomenclature, commonly ac-
cepted names and activating stimuli are summarized in
Table 1.
Each of the MAPKs are activated by specific MAPKKs:
MEK 1/2 for ERK 1/2, MKK3/6 (and possibly MKK4) for
the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for
ERK5 (Fig. 3). The complexity and diversity of the MAPK
signaling pathways is further enhanced due to the activation
of each MAPKK by more than one MAPKKK, thus posi-
tioning MAP kinase modules as focal points of signal con-
vergence and crosstalk, MAPKKKs themselves are regu-
lated by multiple mechanisms (Cobb, 1999; Pearson et al.,
2001). In particular, small GTPases of the Ras family play
important roles in the activation of Raf proteins (the MAP-
KKKs of the ERK pathway) by growth factor receptors,
whereas members of the Rho GTPases family have been
implicated in activation of the JNK and p38 proteins. These
small GTPases therefore also contribute to signal integra-
tion and crosstalk between different MAP kinase modules.
ERK
The first mammalian MAPK pathway to be described
was that of the extracellular signal regulated kinases
(ERKs). Activation of this pathway has subsequently been
observed in a diverse range of cellular activities including
cell proliferation. Regulation of the ERK signaling pathway
occurs largely through the monomeric GTPase Ras which
recruits MAP3Ks of the Raf family to activate MEK1 and
MEK2. These MEKs in turn activate the ERKs (for reviews,
see Avruch et al., 1994; Marais and Marshall, 1996;
Roovers and Assoian, 2000). ERK substrates include the
kinases MSK1/2 and MNK1/2 and the transcription factors
Elk-1 and SAP1.
Three Raf proteins have been described in mammals
with the ubiquitously expressed Raf-1 (c-Raf) having been
the most extensively studied. A-Raf and B-Raf expression
profiles are more limited. All three Raf enzymes however
share Ras as the common upstream activator while MEK
serves as the commonly accepted substrate (Morrison and
Cutler, 1997; Schaeffer and Weber, 1999). The diverse
biological responses activated through this pathway remains
puzzling, but may depend on the strength and/or duration of
ERK activation (Cook et al., 1999; Marshall, 1995; Woods
et al., 1997).
JNK
In contrast to the ERKs, the stress-activated protein ki-
nases (SAPK) or c-Jun NH2-terminal kinases (JNK) (orig-
inally termed p54 or p54-MAP2 kinase) are not strongly
activated by mitogens, such as epidermal growth factor
Table 1
MAPK nomenclature
Name Alternate names Unigene name Unigene cluster Locuslink number OMIM Activating stimuli
ERK1 p44-MAPK MAPK3 Ms. 861 5595 601795 Mitogens
ERK2 p42-MAPK MAPK1 Ms. 3244T3 5594 176948 Mitogens
JNK1 SAPK-, SAPK1c MAPK8 Ms. 267445 5599 601158 Inflammatory cytokines,
stress (e.g. UV, ionizing
radiation antibiotics)
JNK2 SAPK-, SAPK1a MAPK9 Ms. 246857 5601 602896 Inflammatory cytokines,
stress (e.g. UV, ionizing
radiation, antibiotics)
JNK3 SAPK-, SAPK1b, p49F12 MAPK10 Ms. 151051 5602 602897 Inflammatory cytokines,
stress (e.g. UV, ionizing
radiation antibiotics)
p38 SAPK2a, CSBP1, MPK2 MAPK14 Ms. 79107 1432 600289 Inflammatory cytokines,
stress (osmotic shock,
oxidative stress,
anisomycin)
p38 SAPK2b, p38-2 MAPK11 Ms. 57732 5600 602898 Inflammatory cytokines,
stress (osmotic shock,
oxidative stress,
anisomycin)
p38 SAPK3, ERK6 MAPK12 Ms. 55039 6300 602399 Inflammatory cytokines,
stress (osmotic shock,
oxidative stress,
anisomycin)
p38 SAPK4 MAPK13 Ms. 178695 5603 602899 Inflammatory cytokines,
stress (osmotic shock,
oxidative stress,
anisomycin)
ERK5 SAPK5, BMK1 MAPK7 Ms. 3080 5598 602521 Stress, growth factors
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(EGF), but are stimulated in response to inflammatory cy-
tokines of the tumour necrosis factor (TNF) family (TNF,
interleukin-1, CD-40, CD27 ligand, Fas ligand, receptor
activator of NF-B, RANK ligand etc), by vasoactive pep-
tides (endothelin and angiotensin II), and by a variety of
noxious treatments, such as heat shock, ionising radiation,
oxidant stress, DNA damaging chemicals, reperfusion in-
jury, mechanical shear stress, and of course, protein synthe-
sis inhibitors (Kyriakis and Avruch, 1996; Kyriakis et al.,
1994; Pombo et al., 1994). In addition, JNK activation by
TGF- has been reported (Atfi et al., 1997;) Hocevar et al.,
1999; Wang et al., 1997). Upstream activation of JNK
occurs via the MAPKKs MKK4 and MKK7. The MAP3Ks
for the JNK pathway include MEKKs, mixed lineage ki-
nases (MLKs including MLK1–3 and DLK), Tp12, ASK,
and TAK (Davis, 2000; Weston and Davis, 2002).
Ten JNK isoforms, encoded by three different genes,
have been identified in mammalian cells. These isoforms
differ in expression patterns and interactions with down-
stream targets (Gupta et al., 1996). The biological roles of
JNK include the regulation of stress responses and inflam-
mation, as well as the control of cell proliferation, differ-
entiation and apoptosis (Davis, 2000; Weston and Davis,
2002). Interruption of JNK signaling in genetically engi-
neered mice results in defects mostly in the immune and
nervous systems (Pearson et al., 2001).
p38
The third family of mammalian MAPKs is the p38
MAPK family. p38 MAPK was first described by Han et al.,
(1993, 1994) in murine cells exposed to bacterial lipopoly-
saccharide (LPS). Currently, four different p38 genes are
known, some of which undergo alternative splicing. The
various p38 proteins differ in their specificity both for up-
stream activators and downstream substrates. p38 MAP
kinases are activated by a large array of extracellular stim-
uli, including cytokines, growth factors, stress, and integrins
(Adams et al., 2001; Gallo and Johnson, 2002; Nebreda and
Porras, 2000; Ono and Han, 2000; Pearson et al., 2001; Shi
and Gaestel, 2002). While p38 kinases were originally de-
scribed as stress- and inflammation-related kinases, recent
evidence suggest multiple physiological roles in cell cycle
control and in cell proliferation, differentiation and apopto-
sis (Ambrosino and Nebreda, 2001; Nebreda and Porras,
2000; Pearson et al., 2001). p38 kinases also play crucial
roles in the regulation of gene expression through control of
transcription (Raingeaud et al., 1996) as well as RNA (Dean
et al., 1999; Ridley et al., 1998; Winzen et al., 1999) and
protein stability (Bulavin et al., 1999; Casanovas et al.,
2000).
p38 MAP kinases are activated by the upstream kinases
MKK3 and MKK6. Phosphorylation of p38 by MKK4 is
controversial, but analyses of MKK4-deficient mice suggest
that MKK4 involvement in p38 regulation might be cell
type- and stimulus-specific (Ganiatsas et al., 1998). Numer-
ous p38 substrates have been reported. These encompass
various kinases such as MAPKAP K2/3, p38-regulated/
activated protein kinase (PRAK), ribosomal S6 kinase-B
(RSK-B), mitogen and stress-activated kinase 1 (MSK1)/
RLPK, and MAP kinase-interacting kinase 1 and 2 (MNK1/
2), together with transcription factors, such as myocyte
enhancer factor 2 (MEF2), activation transcription factor-2
(ATF-2), C/EBP homologous protein (CHOP), SAP-1A,
and Elk-1, as well as cytosolic proteins such as stathmin
(Fig. 3).
p38 MAPKs are the targets of a class of pyridinyl-
imidazole anti-inflammatory drugs, the cytokine-suppres-
sive anti-inflammatory drugs (CSAIDS). Of these,
SB203580 has been the most extensively characterised
(Cuenda et al., 1995; English and Cobb, 2002) and inhibits
p38 through competition with ATP (Young et al., 1997).
Only p38 and p38 are inhibited by CSAIDS, while p38
and p38 remain completely unaffected (Goedert et al.,
1997; Kumar et al., 1997).
MAP kinases in chondrogenesis
Chondrogenesis is initiated by the condensation of mes-
enchymal precursor cells, which is followed by cell differ-
entiation to chondroblasts and the appearance of cartilage
nodules (Cancedda et al., 2000; DeLise et al., 2000). Im-
portant signaling pathways controlling these stages during
chondrogenesis include the protein kinase C (PKC) and
MAPK pathways. Members within this latter pathway, how-
ever, demonstrate various degrees of participation in chon-
drogenesis. For example, JNK phosphorylation is not af-
fected during chondrogenesis, suggesting that JNKs play
only minor roles in this process (Nakamura et al., 1999). In
contrast, p38s and ERKs occupy central positions in this
process. During chondrogenesis of chick mesenchymal
cells, p38 phosphorylation is increased and ERK phosphor-
ylation is decreased (Oh et al., 2000). In agreement with
this, inhibition of p38 activity blocks chondrogenesis,
whereas inhibition of MEK/ERK activity enhances chon-
drogenesis. Both MAP kinases do not appear to be involved
in the initial condensation step, but affect cartilage nodule
formation (Oh et al., 2000). Furthermore, inhibition of
chondrogenesis by epidermal growth factor (EGF) has been
shown to involve upregulation of ERK phosphorylation and
inhibition of p38 phosphorylation (Yoon et al., 2000). Sim-
ilarly, inhibition of chondrogenesis by rapamycin is accom-
panied by reduced activity of p38 and PKC; however, ERK
activity was not affected in these experiments (Oh et al.,
2001). Finally, suppression of chondrogenesis by retinoic
acid correlates with decreased p38 activity (Weston et al.,
2002). These data thus support opposing roles of p38 and
ERK in chondrogenesis, with p38 being necessary for chon-
drogenesis, whereas ERK signaling represses chondrogen-
esis. However, a recent report demonstrated the requirement
for MEK/ERK signaling for the induction of the chondro-
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genic master gene Sox9 by FGF signaling (Murakami et al.,
2000). Furthermore, stimulation of chondrogenesis of the
mouse chondrogenic cell line ATDC5 by growth and dif-
ferentiation factor 5 (GDF-5), a TGF- family member,
involves both rapid and transient phosphorylation of ERK1
and ERK2, and a slow and sustained phosphorylation of
p38. JNK phosphorylation remains unchanged in response
to GDF-5 (Nakamura et al., 1999).
In summary, these experiments suggest an obligatory
role for p38 in chondrogenesis. p38 and  appear to be of
particular importance in this context, since the described
experiments relied on the pharmacological inhibitors
SB203580 and SB202190, which is specific for these two
p38 forms. The role of ERK appears to be more complex
and may depend on the intensity or duration of upstream
activating signals or localization within the cell.
MAP kinases in chondrocyte proliferation and
hypertrophy
In contrast to the roles of ERK and p38 in chondrogen-
esis, their functions in later stages of chondrocyte matura-
tion are less defined. However, several recent publications
have begun to address the roles of p38 and ERK in chon-
drocyte gene expression, proliferation and hypertrophic dif-
ferentiation. CTGF/Hcs24 (connective tissue growth factor/
hypertrophic chondrocyte specific gene product 24)
promotes proliferation and differentiation of chondrocytes
in culture. Yosimichi et al. (2001) recently demonstrated
that CTGF/Hcs24-induced proliferation of chondrocytes is
mediated through the ERK signaling pathway, while CTGF/
Hcs24-induced differentiation of chondrocytes is mediated
through p38 MAPK. Both ERK and p38 have also been
implicated in TGF- signal transduction in differentiating
chondrocytes. TGF-1 induces a selective, dose-and time-
dependent increase in sodium-dependent transport of inor-
ganic phosphate in chondrogenic ATDC5 cells (Palmer et
al., 2000). In this cell line, TGF-1 induces Smad signaling
pathways as well as ERK and p38 phosphorylation while
JNK phosphorylation remains unaffected. Differences in the
activation kinetics of these kinases are evident with ERK
activation being rapid and transient, as opposed to p38 that
displays a slower and more prolonged activation. Smad2
and ERK activation display similar kinetics but, in contrast
to ERK activation (which is only transient), Smad2 phos-
phorylation is maintained for several hours, similar to p38
MAPK activation.
TGF- also rapidly induces expression of the proteogly-
can aggrecan in ATDC5 cells via the Smad signaling path-
way (Watanabe et al., 2001). At early stages of ATDC5
differentiation, TGF- induced activation of aggrecan gene
expression requires Smad signaling as well as activity of
ERK and p38 MAP kinases. However, it is interesting to
note that following differentiation, aggrecan expression no
longer requires TGF- activated Smads, but is still depen-
dent on both ERK and p38 signaling (Watanabe et al.,
2001).
FGFs play multiple roles in the control of chondrocyte
proliferation and differentiation (Naski and Ornitz, 1998).
ERK phosphorylation is induced by FGF9 and FGF18 in
chondrocytes (Rozenblatt-Rosen et al., 2002; Shimoaka et
al., 2002). ERK phosphorylation in response to FGF9 is
accelerated by thanatophoric dysplasia mutants of the FGF
receptor 3; however, although these mutations act in an
activated manner, no ligand-independent activation of ERK
by FGF receptor 3 was observed (Legeai-Mallet et al.,
1998). FGF18 also induces a transient activation of p38, and
both ERK and p38 are required for the mitogenic actions of
FGF18 on chondrocytes in vitro (Shimoaka et al., 2002).
However, it should be noted that the concentrations of the
p38 inhibitor SB203580 required for these activities are 10
M and higher. At these concentrations the inhibitors may
affect other pathways as well—an important consideration
when using these reagents (Lali et al., 2000). Similar con-
siderations apply to many of the experiments addressing
p38 function described here.
The c-Raf kinase, which is a MAP3K for ERK1/2, has
been shown to be upregulated during chondrocyte differen-
tiation in vivo (Kaneko et al., 1994). Recent evidence from
our laboratory also demonstrated that c-Raf, MEK1/2, and
ERK1/2 are required for the normal expression of the col-
lagen X and p21WAF1/CIP1 genes, which are markers for
hypertrophic chondrocytes (Beier et al., 1999b,c). These
data suggest a role of the c-Raf/MEK1/2-ERK1/2 pathway
in hypertrophic differentiation. In agreement with that, gen-
eration of a hypomorphic allele of c-Raf in mice, where
c-Raf activity is reduced to approximately 10% of wild type
activity, causes a severe delay in growth and endochondral
ossification (Wojnowski et al., 1998). However, it remains
to be shown whether this effect is completely due to a
general developmental delay or to specific roles of c-Raf in
chondrocytes. p38 has been implicated in the control of
collagen X transcription as well (Beier and LuValle, 1999).
Zhen et al. (2000) have shown that suppression of p38
activity is involved in the effects of parathyroid hormone
(PTH) on chicken growth plate chondrocytes. In these ex-
periments, inhibition of p38 signaling resulted in an accu-
mulation of cartilage matrix protein expression, a marker of
prehypertrophic chondrocytes, but suppresses expression of
collagen X, a marker of hypertrophic chondrocytes. These
data suggest that p38 signaling is required for the transition
from the prehypertrophic to the fully hypertrophic chondro-
cyte phenotype.
A recent report suggests that p38, in contrast to ERK and
JNK, is activated by retinoic acid in chondrocytes and is
necessary for the induction of collagenase 3, Cbfa1, and
osteocalcin expression by retinoic acid, which might repre-
sent transdifferentiation of chondrocytes to osteoblast-like
cells (Jimenez et al., 2001). In contrast, inhibition of the
ERK pathway by the MEK1/2 inhibitor PD98059 enhances
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the induction of these genes by retinoic acid. These results
suggest that p38 might play a supportive and ERK a repres-
sive role in chondrocyte-to-osteoblast transdifferentiation.
Upstream activators of MAP kinases in chondrocytes
Only limited data are available on the extracellular reg-
ulators of MAP kinase activity in chondrocytes. As outlined
above, TGF- family members induce p38 and ERK phos-
phorylation with different kinetics (Nakamura et al., 1999;
Palmer et al., 2000; Watanabe et al., 2001). In contrast, p38
phosphorylation appears to be inhibited by PTH (Zhen et
al., 2000). Retinoic acid has been shown to lead to de-
creased p38 activity early in chondrogenesis (Weston et al.,
2002), but activate p38 signaling at late stages (Jimenez et
al., 2001). Receptor tyrosine kinases are crucial regulators
of ERK activity (and potentially other MAP kinases). EGF
stimulates ERK phosphorylation and inhibits p38 phosphor-
ylation in chondroprogenitor cells (Yoon et al., 2000). Sev-
eral other growth factors that activate tyrosine kinase recep-
tors play important roles in chondrocyte physiology, such as
insulin-like growth factors (IGFs) and FGFs. As discussed
above, FGF signaling has been shown to stimulate ERK and
p38 phosphorylation and activity in chondrogenic cells
(Legeai-Mallet et al., 1998; Rozenblatt-Rosen et al., 2002;
Shimoaka et al., 2002). FGF receptor expression is dynam-
ically regulated during chondrocyte differentiation (Ornitz
and Marie, 2002), suggesting that differential activation of
MAP kinases (and other signaling pathways) by the differ-
ent receptors could be responsible for their different biolog-
ical roles in skeletal development. A recent report also
demonstrates that p38 is activated by overexpression of
61 integrins in chicken chondrocytes, implicating a role
for extracellular matrix signaling in the control of p38
activity in chondrocytes, and that p38 signaling is necessary
for collagen II expression in these cells (Segat et al., 2002).
In summary, p38 and ERK MAP kinases are targeted by
many extracellular signals with crucial functions in cartilage
development and therefore likely play important roles in
these processes as well.
MAP kinase signaling is also likely involved in the
transduction of mechanical signals in cartilage develop-
ment. Proliferation and differentiation of chondrocytes (El-
der et al., 2001; Kantomaa et al., 1994; Wu et al., 2001; Wu
and Chen, 2000), as well as endochondral bone growth
(Frost and Schonau, 2001), are regulated by mechanical
forces. Shear stress and loading have been shown to regulate
MAP kinase signaling in articular chondrocytes, potentially
through integrin receptors (Hung et al., 2000; Jin et al.,
2000; Loeser, 2002; Mobasheri et al., 2002). While no
studies have addressed whether similar pathways are active
in differentiating chondrocytes, it appears likely that me-
chanical factors contribute to the regulation of MAP kinase
activity in the developing skeleton.
Potential MAP kinase targets in chondrocytes
The substrates of MAP kinases in chondrocytes remain
unknown. The p38 and JNK substrate ATF-2 is required for
normal growth plate morphogenesis and skeletal develop-
ment (Reimold et al., 1996). However, ATF-2 appears to be
most important for chondrocyte proliferation, in part
through the regulation of the cell cycle genes cyclin D1 and
cyclin A (Beier et al., 1999a, 2000, 2001). In contrast to the
role of p38 in chondrogenesis and hypertrophic differenti-
ation, it is not clear whether p38 (or JNK) is necessary for
chondrocyte proliferation, or whether ATF-2 activity is reg-
ulated through other mechanisms in this phase of the chon-
drocyte life cycle. Similarly, AP-1 factors have been shown
to regulate chondrocyte proliferation and differentiation (Io-
nescu et al., 2001b; Kameda et al., 1997; Wang et al., 1992),
but a possible involvement of MAP kinases as upstream
regulators of AP-1 activity in chondrocytes has not been
investigated. A potential binding site for the p38 target
MEF2 has been described in the collagen X promoter
(Harada et al., 1997). Studies in our lab have identified
multiple potential MEF2 binding sites in human and mouse
collagen X genes and demonstrated that MEF2 activity is
required for full activity of the human collagen X promoter
(L-A.S., A. Wall, and F.B., unpublished observations). The
roles of the numerous other transcription factors and down-
stream kinases targeted by MAP kinases in chondrocytes
still have to be elucidated. Another target of ERK proteins,
the ribosomal S6 kinase 2 (RSK2), is mutated in Coffin-
Lowry syndrome (Trivier et al., 1996), a genetic disease
characterized by mental retardation, reduced growth, and
skeletal and craniofacial malformations (Hanauer and
Young, 2002). These findings suggest a role for RSK2 (and
its upstream regulators) in human cartilage development,
which is in agreement with the roles of the RSK2 targets
c-Fos (Ionescu et al., 2001b; Thomas et al., 2000; Wang et
al., 1992) and CREB (Beier et al., 1999a, 2001; Ionescu et
al., 2001a; Long et al., 2001) in chondrocytes.
Open questions
Current evidence suggests important roles of the ERK
and p38 MAP kinases in various phases of endochondral
ossification. While not all published data necessarily agree
on these roles (in particular for ERK), we have to keep in
mind that the exact biological functions of these kinases
depend on a large number of parameters, including the
nature, intensity, and duration of upstream signals, the cel-
lular localization of the signaling proteins, and crosstalk
with other signaling pathways. For example, it has been
shown that different levels of activation of c-Raf cause
different cellular responses (Sewing et al., 1997; Woods et
al., 1997), and that the duration of ERK activation deter-
mines the behaviour of PC12 (Marshall, 1995). It is there-
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fore plausible that ERK stimulates chondrocyte differentia-
tion under certain conditions and inhibits it under other
circumstances, and that ERK proteins (or other signaling
molecules) have different roles in different phases of chon-
drocyte differentiation. The exact roles of the MAP kinases
in endochondral ossification therefore have to be studied in
more detail, including increased use of in vivo models. Most
of the functional data reviewed were obtained through the
use of pharmacological inhibitors. While still of great value,
these approaches will have to be complemented by genetic
strategies, such as targeted gene inactivation, expression of
dominant-negative kinase mutants, or siRNA technology.
Genetic models, with the exception of the mentioned c-Raf
hypomorphic mice (Wojnowski et al., 1998), did not yet
yield much insight into the functions of MAP kinase mod-
ules in skeletal development, mostly because disruption of
genes in MAP pathways often are either early lethal (there-
by preventing analyses of skeletal development) or have
only very subtle defects, presumably due to genetic redun-
dancy. Generation of double “knockout” mice or cartilage-
specific gene disruption will be required for a more com-
plete analyses of MAP kinase function in cartilage
development. The use of additional model systems (such as
Zebrafish or Xenopus) and novel genomic technologies
(e.g., microarrays, use of Fugu rubripes genomic sequences
for the identification of regulatory DNA elements, etc.) also
promise to provide valuable contributions to a better under-
standing of MAP kinase function in endochondral ossifica-
tion.
Furthermore, the identity and function of important up-
stream regulators, downstream mediators, and target genes
of MAP kinases in chondrocytes will have to be investi-
gated. For example, while p38 proteins appear to play mul-
tiple roles in chondrocyte differentiation, it is not known
which of the multiple upstream kinases (in particular
MAP3Ks) control p38 activity in cartilage. Similarly, only
very few of the potential substrates of MAP kinase signaling
have been studied in cartilage development. It will be of
interest whether any of the MAP kinases regulate the activ-
ity of Sox9 or Cbfa1 (two very important transcription
factors in chondrocyte differentiation) in chondrocytes. Fi-
nally, analyses of the roles of other MAP kinases (such as
ERK5) in chondrocytes and crosstalk among MAP kinases
as well as with other signaling systems will be required for
a deeper understanding of skeletal development and asso-
ciated diseases.
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